/Investor DB

JJDC

Venture capital

New Brunswick · Seed–Series B · 11 people tracked

Find your way into JJDC

Each arrow is one introduction. Sign up to fill in the first one.

897 people can intro you to Tamir

Ask Scott Ashworth to introduce you to Tamir Meiri

You →Scott · together at DocSpera →Tamir

675 people can intro you to Asish

Ask Jamie Chen to introduce you to Asish K. Xavier

You →Jamie · together at Arialys Therapeutics →Asish

491 people can intro you to Marian

Ask Sam Okafor to introduce you to Marian Nakada

You →Sam · together at Navitor Pharmaceuticals →Marian

Sign up to find every way you can get introduced to JJDC

  • Your email: who you already know at JJDC, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the JJDC team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

JJDC is the venture capital arm of Johnson & Johnson, investing since 1973 across medical devices, diagnostics, pharmaceuticals, and consumer health. The firm provides seed through late-stage venture financing to companies whose technologies and business models align with Johnson & Johnson's strategic interests.

Stage
Seed–Series B
Check
$500K – $5M
HQ
New Brunswick, New Jersey, US
Instruments
Equity
Founded
1973
Last 12 months
1 investment
Tracked investments
14
IPOs
2

Team · 11 people

from public directories
Fiona MacLaughlin· Principal, Venture Investments
Hirak Parikh· Principal, Venture Investments
Lior Teitelbaum· Principal, Venture Investments
Wei Wu· Principal, Venture Investments
Biren Mehta· Vice President, Venture Investments
Chris Picariello· President
Gilad Glick· Vice President, Venture Investments
V. Kadir Kadhiresan· Vice President, Venture Investments

What they invest in

from 13 of 14 portfolio companies

Healthtech ×10Biotech ×9AI & Machine Learning ×2Digital Health ×2Medical Devices ×2Data & Infrastructure ×1Deep Tech ×1Longevity ×1

HQs:United States×7China×1United Kingdom×1

Investments · 14 tracked

founders shown can be your intro path

By year:2026 · 12025 · 22024 · 12022 · 12019 · 22017 · 12016 · 12015 · 110 dated

Contineum Therapeuticscontineum-tx.cominNASDAQ: CTNM

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.

BiotechHealthtech

Carmine Stengone(President and Chief Executive Officer)inCarmine N. Stengone(President, Chief Executive Officer and Director)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in

Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonSectoral Asset Management+1 more

Protagonist Therapeuticsprotagonist-inc.comin𝕏NASDAQ: PTGXJul 2015

Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.

BiotechHealthtechMilpitas, US

Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)

BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)

Co-investorsAisling CapitalCanaan PartnersJohnson & Johnson Innovation – JJDCLilly VenturesRA CapitalStarfish Ventures

Accent Therapeuticsaccenttx.comin𝕏Jan 2024

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupJohnson & Johnson Innovation – JJDC+1 more

Aetionaetion.com

Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)

Co-investorsB Capital GroupB4 CapitalBlue Lion GlobalFlare Capital PartnersForesite CapitalLG Technology Ventures+6 more

BrainsGatebrainsgate.com

BrainsGate develops a neurostimulation therapy for stroke patients based on stimulation of the sphenopalatine ganglion (SPG) to increase cerebral blood flow.

BiotechHealthtechMedical Devices

Co-investorsAgate Medical Investments LPCipio PartnersElron VenturesPitangoSpero Ventures

Fusion Pharmaceuticalsfusionpharma.comin𝕏Apr 2019

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

John Valliant(Founder)in

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesPivotal Life SciencesSeroba Life SciencesVenture Ontario+6 more

Mestagmestagtherapeutics.comin𝕏Mar 2026 · $40M

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in

Co-investorsGV (Google Ventures)SV Health InvestorsForbionJohnson & Johnson Innovation – JJDCNorthpond Ventures

Nucleomenucleome.comOct 2022

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalPfizer Ventures

PAQ Therapeuticspaqtx.cominMay 2025

Developing novel KRAS degraders.

Burlington, US

Huaixiang Hao(Founder)in

Co-investorsMRL Ventures FundBioTrack Capital

Ribon Therapeuticsribontx.cominJan 2019 · $65M

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesAbbVieDeerfield Management CompanyNovartis Venture Fund+4 more

Rodin Therapeuticsrodintherapeutics.cominAug 2017

HealthtechCambridge, US

Adam Rosenberg(Executive Officer, Director)in

BoardBruce Booth(Director)inKees Been(Director)Samantha Singer(Director)

Co-investorsGV (Google Ventures)Hatteras Venture PartnersThird Point VenturesAtlas VentureRemeditex Ventures

Ronovo Surgicalronovosurgical.cominSep 2025 · $67M

Ronovo Surgical develops the Carina surgical robotics platform, including a vision system and instruments, for use by surgeons and hospitals.

HealthtechMedical DevicesRoboticsShanghai, CN

John Ma(Founder)inYing Mao(Founder)in

Co-investorsGranite AsiaINCE CapitalVivo CapitalLilly Asia Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

RenovoX-Vax Technology

Exits · 2

2 IPOs

Contineum TherapeuticsNASDAQ: CTNMProtagonist TherapeuticsNASDAQ: PTGX

Portfolio news

latest coverage across their companies

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

CompanyOwnedIPO priceAt IPOStake value
Contineum Therapeutics7.1%$16.00Apr 2024$26.7M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has JJDC made?
JJDC has 14 tracked investments, 2 of which have exited, including 3 dated in the last 24 months.
What stage does JJDC invest at?
JJDC invests at the Seed, Series A, Series B stages.
What is JJDC's typical check size?
JJDC typically writes checks of $500K – $5M.
What sectors does JJDC focus on?
JJDC focuses on Biotech, Consumer, Healthtech, Medical Devices.
Where is JJDC located?
JJDC is headquartered in New Brunswick, US.

Similar investors

Featured in lists